Veradermics, Inc

424B4 priced

Veradermics, Inc. is conducting a public offering of 3,843,790 shares of common stock at $100.00 per share, with gross proceeds of $384.4 million. The offering includes a concurrent private placement (PIPE) of 300,000 pre-funded warrants at $99.99999 per share to Suvretta Capital affiliates. The company is developing VDPHL01, an oral, non-hormonal treatment for pattern hair loss (PHL), with positive Phase 2/3 trial results in male patients. The offering is led by joint book-runners Jefferies, Leerink Partners, Citigroup, and Cantor, with Needham & Company as lead manager.

FWP supplemental

Price $100.00 · 3,843,790 shares · Gross proceeds $384,400,000

Veradermics, Inc. announced the pricing of an upsized public offering of 3,843,790 shares of common stock at $100.00 per share, raising $384.4 million, and a $30.0 million private placement of pre-funded warrants. The offering, led by Jefferies, Needham & Company, and others, is subject to customary closing conditions. The filing serves as a prospectus for the offering, following the effectiveness of its S-1 registration.

EFFECT effective

Veradermics, Inc. has received SEC approval for its Form S-1 registration statement, enabling the proposed public offering of 3,350,000 shares of common stock and pre-funded warrants. The offering includes a 30-day underwriter option to purchase additional shares, alongside a private placement of pre-funded warrants to Suvretta Capital entities. The company aims to advance its hair loss treatment pipeline, including VDPHL01, a non-hormonal oral therapy.

FWP supplemental

3,350,000 shares

Veradermics, Inc. has launched a public offering of 3,350,000 shares of common stock and pre-funded warrants, with underwriters holding a 30-day option to purchase an additional 502,500 shares. A concurrent private placement with Suvretta Capital entities will reduce the public offering size on a one-for-one basis. The offering is subject to market conditions and regulatory approvals, with forward-looking statements cautioning about uncertainties.

S-1 filed

3,350,000 shares

Veradermics, Inc. is conducting an IPO to raise capital through the offering of 3,350,000 shares of common stock and pre-funded warrants. The company is developing VDPHL01, an oral, non-hormonal treatment for pattern hair loss (PHL), with ongoing Phase 2/3 and Phase 3 trials in male and female patients. The offering includes a concurrent private placement (PIPE) with Suvretta Capital, and the company highlights its focus on addressing significant unmet needs in PHL treatment. The filing reflects a transition from a confidential DRS submission to a public S-1 registration.

DRS filed

Veradermics, Inc. is preparing for a securities offering, as indicated by its DRS filing dated April 6, 2026. The company is a biopharmaceutical firm focused on developing VDPHL01, an oral, non-hormonal treatment for pattern hair loss (PHL). The filing outlines ongoing clinical trials for VDPHL01, including pivotal studies in male and female patients, with topline data expected in 2026. The offering details remain preliminary, with placeholders for share quantities, pricing, and underwriting terms. The company emphasizes its status as an emerging growth company and smaller reporting company.

424B4 priced

Price $17.00 · 15,077,647 shares · Gross proceeds $238,377,599

Veradermics, Inc. is conducting its initial public offering (IPO) of 15,077,647 shares of common stock at $17.00 per share, with the stock set to list on the NYSE under the symbol 'MANE.' The company is developing VDPHL01, an oral, non-hormonal treatment for pattern hair loss (PHL), with ongoing Phase 2/3 clinical trials for both male and female patients. The offering includes underwriting discounts, with potential additional shares via an underwriter option. Key investors include Eli Lilly and Wellington Management, though their participation is not binding.

CERT inactive

Veradermics, Inc. has filed a registration statement with the SEC for its IPO, supplementing the preliminary prospectus with updated information. The current filing highlights ongoing interest from major investors, including Eli Lilly and Wellington Management, though these indications remain non-binding. The document emphasizes the need to review the preliminary prospectus and other SEC filings for complete details.

FWP supplemental

Veradermics, Inc. has filed a free writing prospectus (FWP) relating to its upcoming initial public offering (IPO), supplementing the preliminary prospectus included in its S-1 registration statement. The filing highlights indications of interest from major investors, including Eli Lilly and Company (up to 4.9% of shares) and Wellington Management (up to $30 million in shares) for the offering. The document emphasizes that these commitments are non-binding and may affect the public float if executed.

8-A12B effective

Veradermics, Inc. filed Form 8-A12B to register its common stock, $0.00001 par value per share, on the New York Stock Exchange. The filing incorporates by reference the securities description from its prior S-1 registration statement (File No. 333-292657), which was initially filed on January 9, 2026. The current filing confirms the company's intent to comply with Section 12(b) of the Securities Exchange Act of 1934.

EFFECT effective

Veradermics, Inc. has filed an S-1 registration statement, which became effective on January 30, 2026. The company is offering 13,350,000 shares of common stock in its initial public offering (IPO), with an expected price range of $14.00 to $16.00 per share. The offering is underwritten by Jefferies, Leerink Partners, Citigroup, and Cantor. Veradermics, an emerging growth company, highlights risks including market competition, regulatory challenges, and dependence on key personnel. Proceeds will be used for general corporate purposes, and the company anticipates listing on the NYSE under the symbol 'MANE'.

S-1/A amended

Price $15.00 · Range $14.00 to $16.00 · 13,350,000 shares · Gross proceeds $213,600,000

Veradermics, Inc. is conducting its initial public offering (IPO) to raise capital for the development of VDPHL01, an oral, non-hormonal treatment for pattern hair loss (PHL). The company aims to address limitations in current PHL treatments through a novel extended-release formulation of minoxidil. The IPO involves 13,350,000 shares of common stock with an expected price range of $14.00 to $16.00 per share. The offering includes a cornerstone investment commitment of up to $30.0 million from Wellington Management and underwriting agreements with Jefferies, Leerink Partners, Citigroup, and Cantor. The company is in late clinical-stage development, with pivotal trials ongoing for both male and female patients.

S-1 filed

Veradermics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its late-stage clinical program for VDPHL01, an oral, non-hormonal treatment for pattern hair loss (PHL). The company is seeking FDA approval for VDPHL01 through a 505(b)(2) NDA, with ongoing Phase 2/3 trials in male and female patients. The IPO is contingent on listing on the New York Stock Exchange under the symbol 'MANE'. The filing highlights the potential of VDPHL01 to address unmet needs in PHL treatment, including faster hair regrowth and improved tolerability compared to existing options.

DRS filed

Veradermics, Inc. is conducting clinical trials for VDPHL01, an oral non-hormonal treatment for pattern hair loss (PHL), aiming to address limitations of current therapies. The company is preparing for its initial public offering (IPO) with an expected listing on the NYSE. VDPHL01 is in registration-directed Phase 3 trials for male and female patients, with data expected in 2025. The filing highlights the drug's potential as the first FDA-approved oral, non-hormonal PHL treatment, while noting risks related to clinical trial outcomes, regulatory approvals, and market competition.